EGFR and non-small cell lung carcinoma: They reported worse OS for patients with PD-L1 positive EGFRm NSCLC versus PD-L1 negative (median OS 15.2 versus 29.3 months, p = 0.006), though most of these patients received EGFR TKI monotherapy across all lines of treatment.